Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus
Journal of General Virology, Volume 87, No. 3, Year 2006
Notification
URL copied to clipboard!
Description
Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by β-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection. © 2006 SGM.
Authors & Co-Authors
See, Raymond H.
Canada, Vancouver
The University of British Columbia
Rowe, Thomas
United States, Birmingham
Southern Research
Karunakaran, Karuna P.
Canada, Vancouver
The University of British Columbia
Hitt, Mary M.
Canada, Hamilton
Mcmaster University
Canada, Edmonton
Cross Cancer Institute
Mahony, James B.
Canada, Hamilton
Mcmaster University
Scheifele, David W.
Canada, Vancouver
Children's and Women's Health Centre of British Columbia
Skowronski, Danuta M.
Canada, Vancouver
The University of British Columbia
Patrick, David M.
Canada, Vancouver
The University of British Columbia
Babiuk, Lorne A.
Canada, Saskatoon
University of Saskatchewan
Roper, Rachel L.
United States, Greenville
East Carolina University
Brunham, Robert C.
Canada, Vancouver
The University of British Columbia
Finlay, Barton Brett
Canada, Vancouver
The University of British Columbia
Statistics
Citations: 127
Authors: 12
Affiliations: 12
Identifiers
Doi:
10.1099/vir.0.81579-0
ISSN:
00221317
Research Areas
Covid